Market Overview - The Hang Seng Index rose by 0.61%, gaining 161 points to close at 26,406 points, while the Hang Seng Tech Index increased by 0.12%. The morning trading volume in Hong Kong reached 114.1 billion HKD [1]. Company Highlights - China Duty Free Group (601888) (01880) saw a surge of over 13% as the new duty-free policy in Hainan shows positive effects, with institutions suggesting a potential industry turning point [1]. - Pop Mart (09992) increased by over 6% due to gradual capacity expansion, with management expecting stronger sales performance in Q4 [1]. - Dongyang Sunshine Pharmaceutical (600673) (06887) rose by over 4% as flu activity is on the rise, and institutions are optimistic about the company's innovative pipeline development [1]. - China Liansu (02128) gained over 5% as the company is expected to benefit significantly from urban pipeline upgrades under the 14th Five-Year Plan [1]. - Hou Shang Ayi (02589) increased by over 8% after the company proposed adopting an H-share incentive plan, successfully entering the "10,000-store club" [1]. - Education stocks performed well, with institutions noting overall good performance in the education sector and the potential for AI+ education to enhance valuation. China Education Holdings (00839) rose by 8%, Thinking Academy (01769) by 3.3%, and New Oriental-S (09901) by 3.25% [1]. - Ruipu Lanjun (00666) increased by over 6% as global demand for energy storage remains strong, with the company reporting over 50 GWh of energy storage battery shipments in the first three quarters [1]. - Gilead Sciences-B (01672) rose by over 6% after being included in the MSCI Global Small Cap Index, with significant weight loss effects from ASC30 [1]. - Goldwind Technology (002202) (02208) fell by over 5% as a major shareholder, Harmony Health, plans to further reduce its stake by up to 1%, following a previous reduction at the end of last month [1]. - Robotics concept stocks declined, with DCH Holdings (00179) dropping over 4% and Sanhua Intelligent Controls (002050) (02050) falling over 3% [1].

Group 1: Market Overview - The Hang Seng Index rose by 0.61%, gaining 161 points to close at 26,406 points, while the Hang Seng Tech Index increased by 0.12%. The morning trading volume in Hong Kong was HKD 114.1 billion [1]. Group 2: Company Highlights - China Duty Free Group (01880) saw a rise of over 13% as the new duty-free policy in Hainan shows early positive effects, with institutions suggesting a potential industry turning point [1]. - Pop Mart (09992) increased by over 6% due to gradual capacity expansion, with management expecting stronger sales performance in Q4 [1]. - Dongyang Sunshine Pharmaceutical (06887) rose by over 4% as flu activity is on the rise, and institutions are optimistic about the company's innovative pipeline development [1]. - China Liansu (02128) increased by over 5% as the 14th Five-Year Plan emphasizes pipeline network renovation, which the company is expected to benefit significantly from [2]. - Shanghai Auntie (02589) rose by over 8% as the company proposed adopting an H-share incentive plan and successfully entered the "10,000-store club" [3]. - Education stocks performed well, with overall positive performance in the education sector, driven by AI+ education enhancing valuation space. China Education Group (00839) rose by 8%, Thinking Academy (01769) by 3.3%, and New Oriental-S (09901) by 3.25% [3]. - Ruipu Lanjun (00666) increased by over 6% due to a favorable global demand for energy storage, with the company reporting over 50 GWh of energy storage battery shipments in the first three quarters [4]. - Gilead Sciences-B (01672) rose by over 6% after being included in the MSCI Global Small Cap Index, with significant weight loss effects from ASC30 [5]. Group 3: Market Declines - Goldwind Technology (02208) fell by over 5% as a shareholder, Harmony Health, plans to further reduce its stake by up to 1%, following a previous reduction at the end of last month [6]. - Robotics concept stocks declined, with DCH Holdings (00179) dropping over 4% and Sanhua Intelligent Control (02050) falling over 3% [7].

Core Viewpoint - Gilead Sciences-B (01672) saw a significant increase of over 7%, currently trading at 10.11 HKD, with a transaction volume of 21.57 million HKD, following its inclusion in the MSCI Global Small Cap Index, effective after the market close on November 24 [1] Group 1: MSCI Inclusion - Gilead Sciences-B has been included in the MSCI Global Small Cap Index as announced by MSCI on November 6 [1] - The adjustment from MSCI will take effect after the market closes on November 24 [1] Group 2: Clinical Research Updates - Gilead Sciences-B presented multiple reports at the 2025 ObesityWeek in Atlanta, Georgia, including a complete analysis of the ASC30 oral tablet Phase Ib study [1] - The ASC30 oral tablet study showed an average weight loss of up to 6.5% after placebo adjustment, demonstrating good safety and tolerability with only mild to moderate gastrointestinal adverse events [1] - The apparent half-lives of the ASC30 injection were 46 days and 75 days, supporting monthly and quarterly dosing regimens [1]

Core Viewpoint - Gilead Sciences-B (01672) saw a stock increase of over 7%, currently trading at 10.11 HKD, following its inclusion in the MSCI Global Small Cap Index, effective after market close on November 24 [1] Group 1: Stock Performance - Gilead Sciences-B's stock rose by 6.98%, with a trading volume of 21.57 million HKD [1] Group 2: MSCI Inclusion - On November 6, MSCI announced the results of its November index review, which included Gilead Sciences-B in the MSCI Global Small Cap Index [1] Group 3: Clinical Research Updates - Gilead Sciences-B presented multiple reports at the 2025 ObesityWeek in Atlanta, Georgia, including a complete analysis of the ASC30 oral tablet Phase Ib study [1] - The ASC30 oral tablet study showed an average weight loss of up to 6.5% after placebo adjustment, demonstrating good safety and tolerability with only mild to moderate gastrointestinal adverse events [1] - The apparent half-lives of the ASC30 injection were 46 days and 75 days, supporting monthly and quarterly dosing regimens [1]

Group 1 - MSCI announced the results of the November index review, with adjustments effective after the market close on November 24 [1] - The MSCI Global Small Cap Index will include 22 new stocks, such as Gilead Sciences (01672) and Meili Tianyuan Healthcare (02373) [1] - 17 stocks will be removed from the MSCI Global Small Cap Index, including China Gold International (02099) and China Nonferrous Mining (01258) [1] Group 2 - The MSCI Hong Kong Index will add 7 new stocks, including Chow Sang Sang (00116) and MGM China (02282) [2] - Stocks removed from the MSCI Hong Kong Index include Kintor Pharmaceutical (02171) and HKT Trust (00215) [2][3]

Group 1 - MSCI announced the results of the November index review, with adjustments effective after the market close on November 24 [1] - A total of 22 stocks were added to the MSCI Global Small Cap Index, including companies such as Genscript Biotech (01672) and Youzan (08083) [1] - 17 stocks were removed from the MSCI Global Small Cap Index, including China Gold International (02099) and Longi Green Energy (601869) [1] Group 2 - The MSCI Hong Kong Index included 7 new stocks, such as Chow Sang Sang (00116) and MGM China (02282) [2] - The MSCI Hong Kong Index removed stocks like Kintor Pharmaceutical (02171) and HKT Trust (00215) [2][3]

Group 1 - The company, Gilead Sciences-B (01672), announced a share buyback program on November 5, 2025, with an expenditure of approximately HKD 924,000 to repurchase 100,000 shares [1] - The repurchase price per share ranged from HKD 9.1 to HKD 9.32 [1]

Group 1 - Company repurchased 100,000 shares at a cost of HKD 924,000 on November 5 [1] - The repurchase is part of the company's strategy to manage its capital and enhance shareholder value [1] - The company is preparing for the complete analysis of the ASC30 oral tablet Phase Ib study at the 2025 ObesityWeek® [1] Group 2 - The company is also conducting Phase Ib studies for ASC30 injection and preclinical studies for ASC31 and ASC47 combination therapy [1]

Group 1 - The company, Gilead Sciences-B (01672), announced a share buyback program on November 5, 2025, with an investment of approximately HKD 924,000 to repurchase 100,000 shares [1] - The repurchase price per share ranges from HKD 9.1 to HKD 9.32 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年11月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...